Monday, October 17, 2022 from 11:00 AM to 12:30 PM PDT at Imperial Ballroom A
Available for 1.50 hours of CPE credit
Activity Number: 0204-9999-22-287-L01-P
Activity Type: An Application-Based Activity
More than 6 million Americans are living with Alzheimer’s disease (AD) and another 1 million are living with Parkinson’s disease (PD). Advances have been made in the management of both illnesses; however, models suggest there may be barriers to their practical use. This session will address AD immunotherapies on the breakthrough pathway, focusing on the appropriate use of approved therapies, expectations for emerging therapies, potential barriers to use and subsequent place in therapy. The role of the pharmacist in closing gaps in screening, diagnosis, and treatment for AD will be emphasized. Furthermore, the session will address the place in therapy for new medications and formulations approved to treat motor, non-motor, and psychiatric complications of PD. Attendees will participate in case-based learning scenarios via the audience response system that reflect realistic clinical decisions for both AD and PD. Covered content will also extend beyond the clinical use of medications and will prompt learners to consider broader societal implications of medication use (e.g., formulary coverage, continuation and discontinuation).
The BCACP/BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified ambulatory care pharmacists and/or geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP and/or BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCACP/BCGP Clinical Sessions posttests will be available on December 14, 2022, at www.accp.com/myaccount to anyone who has purchased access to the BCACP and/or BCGP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 18, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 12, 2023.
Learning Objectives
1. Explain the mechanisms of anti-amyloid antibodies on the breakthrough therapy pathway.
2. Evaluate anti-amyloid antibody treatment criteria, including strategies to mitigate and monitor for CNS adverse events in eligible patients.
3. Assess implications of anti-amyloid immunotherapy approval and potential barriers to routine use.
4. Develop an individualized treatment plan to optimize motor symptoms of PD utilizing novel therapies.
5. Evaluate the use of medications for the treatment of non-motor symptoms of PD.